Surprising outcome: Hydroxurea vs. Interferon
Ropeginterferon disappoints…MPD-RC delivers….momelotinib scores
Views: Crispino, Harrison, Mascarenhas, Mesa, Scherber, Silver, Spivak, Stein, Verstovsek
Precision medicine, imprecise drugs: MPN treatment enters 2017.
For the MPN community, the American Society of Hematology meeting in San Diego was a mixed bag. Our knowledge of driving mutations clearly advanced but once again we return from the annual meeting empty-handed. No new drugs, terrible news on the CAR-T immunotherapy front (seven deaths, five on an acute leukemia trial) and no breakthrough meds in sight. Last year’s contenders — imetelstat, PRM-151, pacritinib — are either on clinical hold or no-shows. But all is not lost. We have new weapons against anemia, new treatment options, improved SCT options and new clinical trials. Maybe next year.
Contents… (Click on red link to access story)
Hydroxyurea vs. Interferon — Big European and US trials agree on shocking verdict in the first round.
Momelotinib — “Things are very good.” Behind the data, stories from two patients on the Baltimore clinical trial.
Expert takeaways from ASH — Cliff Notes on ASH from the very best in the business.
We owe this issue to our 2016 MPNforum Sponsors, see: The Charming Gardeners,
* Photo Credit: Sand Sculpture photo by Barbara Kurtz
The MPN Genetics Network .. Report on CRISPR gene therapy
- And thanks to Jane Frantz for a ton of proofreading. (The remaining errors are entirely due to the Editor’s haste.)
Tell your story, express yourself, share your experience in your MPN magazine. You can add your comments to MPNforum articles, list your Blog, or write an article. (We’ll even help you get started.)…Letter to the Editor
For information Contact: ourMPNforum@gmail.com
© MPNforum, LLC , MPNforum.com, and the MPNforum Quarterly Journal 2016. MPNforum is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. Reproduction is permitted provided full and clear credit is given to authors and MPNforum.com with appropriate and specific direction to the original content.